If you look carefully at the available assays from these three companies, they cover mostly the clinical chemistry arena.

Theranos was claiming to be able to perform complex immunoassays on their devices. Microfluidic immunoassays are very tough to get right, given the extremely small size of the patient sample and the even smaller concentrations of analyte in the patient's bloodstream.